Is ALMS or DSGN more profitable?

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Design Therapeutics' return on equity of -34.03% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Design Therapeutics N/A -34.03% -32.05%

Does the media favor ALMS or DSGN?

In the previous week, Alumis had 18 more articles in the media than Design Therapeutics. MarketBeat recorded 19 mentions for Alumis and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.77 beat Alumis' score of -0.13 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GMTX or DSGN?

Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 8.06%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has stronger valuation and earnings, GMTX or DSGN?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Design Therapeutics N/A N/A -$69.79M -$1.18 N/A

Is GMTX or DSGN more profitable?

Design Therapeutics' return on equity of -34.03% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Design Therapeutics N/A -34.03% -32.05%

Is DSGN or CLDX more profitable?

Design Therapeutics' return on equity of -34.03% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -34.03% -32.05% Celldex Therapeutics N/A -52.35% -47.61%

Does the media refer more to DSGN or CLDX?

In the previous week, Celldex Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 2 mentions for Celldex Therapeutics and 1 mentions for Design Therapeutics. Celldex Therapeutics' average media sentiment score of 1.14 beat Design Therapeutics' score of 0.77 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GRAL or DSGN?

In the previous week, GRAIL had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for GRAIL and 1 mentions for Design Therapeutics. GRAIL's average media sentiment score of 1.25 beat Design Therapeutics' score of 0.77 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAMS or DSGN?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 1 mentions for Design Therapeutics. NewAmsterdam Pharma's average media sentiment score of 1.49 beat Design Therapeutics' score of 0.77 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Design Therapeutics (DSGN) Competitors

$15.27 +0.17 (+1.13%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$15.27 0.00 (0.00%)

As of 08/18/2026 07:30 PM Eastern

Compare

DSGN vs. ALMS, GMTX, CLDX, GRAL, and NAMS

Should you buy Design Therapeutics stock or one of its competitors? Design Therapeutics's main competitors and comparable companies include Alumis (ALMS), Gemini Therapeutics (GMTX), Celldex Therapeutics (CLDX), GRAIL (GRAL), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Design Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Alumis has a beta of -0.69, suggesting that its stock price is 169% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

Design Therapeutics has lower revenue, but higher earnings than Alumis. Design Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	131.89	-$243.32M	-$3.86	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

In the previous week, Alumis had 18 more articles in the media than Design Therapeutics. MarketBeat recorded 19 mentions for Alumis and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.77 beat Alumis' score of -0.13 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis currently has a consensus target price of $40.30, indicating a potential upside of 61.98%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 8.06%. Given Alumis' higher possible upside, equities analysts clearly believe Alumis is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

56.6% of Design Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Design Therapeutics' return on equity of -34.03% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Design Therapeutics	N/A	-34.03%	-32.05%

Summary

Design Therapeutics beats Alumis on 9 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Design Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Design Therapeutics and 0 mentions for Gemini Therapeutics. Design Therapeutics' average media sentiment score of 0.77 beat Gemini Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Design Therapeutics	Positive

Design Therapeutics' return on equity of -34.03% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Design Therapeutics	N/A	-34.03%	-32.05%

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 8.06%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats Gemini Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Celldex Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Design Therapeutics has higher earnings, but lower revenue than Celldex Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Celldex Therapeutics	$1.54M	2,131.02	-$258.76M	-$4.35	N/A

Design Therapeutics' return on equity of -34.03% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Celldex Therapeutics	N/A	-52.35%	-47.61%

56.6% of Design Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Design Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 8.06%. Celldex Therapeutics has a consensus price target of $55.46, suggesting a potential upside of 32.71%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Celldex Therapeutics had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 2 mentions for Celldex Therapeutics and 1 mentions for Design Therapeutics. Celldex Therapeutics' average media sentiment score of 1.14 beat Design Therapeutics' score of 0.77 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Design Therapeutics beats Celldex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

GRAIL has a beta of 3.24, meaning that its stock price is 224% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

In the previous week, GRAIL had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for GRAIL and 1 mentions for Design Therapeutics. GRAIL's average media sentiment score of 1.25 beat Design Therapeutics' score of 0.77 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.6% of Design Therapeutics shares are owned by institutional investors. 1.8% of GRAIL shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Design Therapeutics has lower revenue, but higher earnings than GRAIL. Design Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	21.52	-$408.35M	-$9.75	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Design Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Design Therapeutics	N/A	-34.03%	-32.05%

GRAIL currently has a consensus price target of $67.78, suggesting a potential downside of 4.39%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 8.06%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

NewAmsterdam Pharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Design Therapeutics' return on equity of -34.03% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Design Therapeutics	N/A	-34.03%	-32.05%

NewAmsterdam Pharma presently has a consensus price target of $49.33, suggesting a potential upside of 81.04%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 8.06%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 1 mentions for Design Therapeutics. NewAmsterdam Pharma's average media sentiment score of 1.49 beat Design Therapeutics' score of 0.77 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. Design Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$7.12M	457.43	-$203.82M	-$2.16	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Design Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$928.09M	$3.74B	$7.06B	$13.09B
Dividend Yield	N/A	3.69%	2.56%	10.63%
P/E Ratio	-12.94	11.65	270.28	24.33
Price / Sales	N/A	1,355.41	676.02	125.40
Price / Cash	N/A	44.90	28.88	38.50
Price / Book	4.09	17.73	11.29	6.43
Net Income	-$69.79M	-$12.50M	$3.46B	$348.18M
7 Day Performance	4.16%	1.00%	0.86%	-0.08%
1 Month Performance	21.48%	3.18%	2.56%	1.47%
1 Year Performance	195.36%	59.20%	26.82%	21.05%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	0.8807 of 5 stars	$15.27 +1.1%	$16.50 +8.1%	+182.8%	$928.09M	N/A	N/A	40	Positive News High Trading Volume
ALMS Alumis	3.1545 of 5 stars	$25.37 -7.8%	$40.30 +58.8%	+413.0%	$3.51B	$24.05M	N/A	N/A	Trending News Earnings Report Analyst Forecast Analyst Revision
GMTX Gemini Therapeutics	N/A	$78.28 +1.1%	N/A	+33.7%	$3.39B	N/A	N/A	30
CLDX Celldex Therapeutics	2.7524 of 5 stars	$44.33 +3.2%	$55.46 +25.1%	+70.7%	$3.37B	$1.54M	N/A	150
GRAL GRAIL	0.9109 of 5 stars	$75.48 +0.9%	$67.78 -10.2%	+116.1%	$3.34B	$147.17M	N/A	1,360	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. ALMS, GMTX, CLDX, GRAL, and NAMS

How does Design Therapeutics compare to Alumis?

Summary

How does Design Therapeutics compare to Gemini Therapeutics?

Summary

How does Design Therapeutics compare to Celldex Therapeutics?

Summary

How does Design Therapeutics compare to GRAIL?

Summary

How does Design Therapeutics compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. ALMS, GMTX, CLDX, GRAL, and NAMS

How does Design Therapeutics compare to Alumis?

Which has more volatility & risk, ALMS or DSGN?

Which has preferable valuation and earnings, ALMS or DSGN?

Does the media favor ALMS or DSGN?

Do analysts prefer ALMS or DSGN?

Do institutionals & insiders have more ownership in ALMS or DSGN?

Is ALMS or DSGN more profitable?

Summary

How does Design Therapeutics compare to Gemini Therapeutics?

Do insiders & institutionals hold more shares of GMTX or DSGN?

Does the media favor GMTX or DSGN?

Is GMTX or DSGN more profitable?

Which has stronger valuation and earnings, GMTX or DSGN?

Which has more risk & volatility, GMTX or DSGN?

Do analysts prefer GMTX or DSGN?

Summary

How does Design Therapeutics compare to Celldex Therapeutics?

Which has more risk and volatility, DSGN or CLDX?

Which has stronger earnings & valuation, DSGN or CLDX?

Is DSGN or CLDX more profitable?

Do institutionals & insiders hold more shares of DSGN or CLDX?

Do analysts rate DSGN or CLDX?

Does the media refer more to DSGN or CLDX?

Summary

How does Design Therapeutics compare to GRAIL?

Which has more risk & volatility, GRAL or DSGN?

Does the media refer more to GRAL or DSGN?

Do insiders & institutionals hold more shares of GRAL or DSGN?

Which has higher earnings & valuation, GRAL or DSGN?

Is GRAL or DSGN more profitable?

Do analysts rate GRAL or DSGN?

Summary

How does Design Therapeutics compare to NewAmsterdam Pharma?

Which has more volatility & risk, NAMS or DSGN?

Is NAMS or DSGN more profitable?

Do analysts recommend NAMS or DSGN?

Does the media prefer NAMS or DSGN?

Which has better valuation & earnings, NAMS or DSGN?

Do institutionals & insiders hold more shares of NAMS or DSGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools